Alkermes
artistry responses in renal cell carcinoma patients | Alkermes
Company
Deck Type
Sector
Industry
Deck date
June 2021
Slide
14 of 31
Similar slides by Alkermes
See diffirences between slides (animation)
Results
June 2021
artistry responses in melanoma patients | Alkermes
Investor Day
March 2021
artistry responses in experienced melanoma patients tumor type line of therapy new cutaneous melanoma partial response evaluation of evaluation of evaluation of ongoing to with time on study weeks artistry part efficacy preliminary data ongoing study out of evaluable patients with scans total responses observed with tumor shrinkage mucosal melanoma and cutaneous melanoma majority of patients are ongoing as of march data cut inhibitors intravenous progressive disease partial response recommended phase dose stable disease reported after the data cut off and awaiting confirmation data cut off march experienced seers fee roe sails a | Alkermes
Related slides by other companies
Genelux
Investor Presentation
December 2023
cells infiltrating lymphocytes are prognostic for response survival | Genelux
Nuvalent
Investor Presentation
February 2024
activity induced intracranial responses in patients with refractory alk phase refractory complete response alk fusion alk fusion no known resistance mutations lines of therapy including and chemotherapy complete resolution of parietal parenchymal brain metastases after weeks treatment continues at months ongoing mutation weeks resistance alk fusion partial response ongoing confirmed lines of therapy consisting treatment continues at after weeks of and months weeks confirmed courtesy of and hospital vall barcelona courtesy of university united states data as of august central nervous system complete response non small source lin cell lung cancer partial response once daily tyrosine kinase inhibitor | Nuvalent
MindMed
Investor Presentation
November 2024
continued response and remission through week with clinical responder rate and clinical remission rate | MindMed
Aeglea BioTherapeutics
Investor Presentation
August 2020
demonstrates durable clinical response at week analysis | Aeglea BioTherapeutics
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights